Literature DB >> 10358180

Absolute requirement for an active immune response involving B cells and Th cells in immunity to Plasmodium yoelii passively acquired with antibodies to the 19-kDa carboxyl-terminal fragment of merozoite surface protein-1.

C Hirunpetcharat1, P Vukovic, X Q Liu, D C Kaslow, L H Miller, M F Good.   

Abstract

Vaccination of mice with the leading malaria vaccine candidate homologue, the 19-kDa carboxyl terminus of merozoite surface protein-1 (MSP119), results in sterile immunity to Plasmodium yoelii, with no parasites detected in blood. Although such immunity depends upon high titer Abs at challenge, high doses of immune sera transferred into naive mice reduce parasitemia (and protect from death) but do not result in a similar degree of protection (with most mice experiencing high peak parasitemias); this finding suggests that ongoing parasite-specific immune responses postchallenge are essential. We analyzed this postchallenge response by transferring Abs into manipulated but malaria-naive mice and observed that Abs cannot protect SCID, nude, CD4+ T cell-depleted, or B cell knockout mice, with all mice dying. Thus, in addition to the Abs that develop following MSP119 vaccination, a continuing active immune response postchallenge is required for protection. MSP119-specific Abs can adoptively transfer protection to strains of mice that are not protected following vaccination with MSP119, suggesting that the Ags targeted by the immune response postchallenge include Ags apart from MSP119. These data have important implications for the development of a human malaria vaccine.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10358180

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  28 in total

1.  Immunoglobulin G3 antibodies specific for the 19-kilodalton carboxyl-terminal fragment of Plasmodium yoelii merozoite surface protein 1 transfer protection to mice deficient in Fc-gammaRI receptors.

Authors:  P Vukovic; P M Hogarth; N Barnes; D C Kaslow; M F Good
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

2.  Nature and specificity of the required protective immune response that develops postchallenge in mice vaccinated with the 19-kilodalton fragment of Plasmodium yoelii merozoite surface protein 1.

Authors:  Jiraprapa Wipasa; Huji Xu; Morris Makobongo; Michelle Gatton; Anthony Stowers; Michael F Good
Journal:  Infect Immun       Date:  2002-11       Impact factor: 3.441

3.  An engineered Plasmodium falciparum C-terminal 19-kilodalton merozoite surface protein 1 vaccine candidate induces high levels of interferon-gamma production associated with cellular immune responses to specific peptide sequences in Gambian adults naturally exposed to malaria.

Authors:  C Bisseye; L M Yindom; J Simporé; W D Morgan; A A Holder; J Ismaili
Journal:  Clin Exp Immunol       Date:  2011-12       Impact factor: 4.330

4.  Alteration in host cell tropism limits the efficacy of immunization with a surface protein of malaria merozoites.

Authors:  Qifang Shi; Amy Cernetich; Thomas M Daly; Gina Galvan; Akhil B Vaidya; Lawrence W Bergman; James M Burns
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

5.  Protection against Plasmodium chabaudi malaria induced by immunization with apical membrane antigen 1 and merozoite surface protein 1 in the absence of gamma interferon or interleukin-4.

Authors:  James M Burns; Patrick R Flaherty; Payal Nanavati; William P Weidanz
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

6.  Why functional pre-erythrocytic and bloodstage malaria vaccines fail: a meta-analysis of fully protective immunizations and novel immunological model.

Authors:  D Lys Guilbride; Pawel Gawlinski; Patrick D L Guilbride
Journal:  PLoS One       Date:  2010-05-19       Impact factor: 3.240

7.  Plasmodium berghei circumvents immune responses induced by merozoite surface protein 1- and apical membrane antigen 1-based vaccines.

Authors:  Shigeto Yoshida; Hiroshi Nagumo; Takashi Yokomine; Hitomi Araki; Ayaka Suzuki; Hiroyuki Matsuoka
Journal:  PLoS One       Date:  2010-10-28       Impact factor: 3.240

8.  Analysis of immunological nonresponsiveness to the 19-kilodalton fragment of merozoite surface Protein 1 of Plasmodium yoelii: rescue by chemical conjugation to diphtheria toxoid (DT) and enhancement of immunogenicity by prior DT vaccination.

Authors:  Danielle I Stanisic; Laura B Martin; Xue Q Liu; David Jackson; Juan Cooper; Michael F Good
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441

9.  Induction of specific T-cell responses, opsonizing antibodies, and protection against Plasmodium chabaudi adami infection in mice vaccinated with genomic expression libraries expressed in targeted and secretory DNA vectors.

Authors:  A Rainczuk; T Scorza; P M Smooker; T W Spithill
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

10.  Cellular responses to modified Plasmodium falciparum MSP119 antigens in individuals previously exposed to natural malaria infection.

Authors:  Christian M F Okafor; Chiaka I Anumudu; Yusuf O Omosun; Chairat Uthaipibull; Idowu Ayede; Henrietta O Awobode; Alex B Odaibo; Jean Langhorne; Anthony A Holder; Roseangela I Nwuba; Marita Troye-Blomberg
Journal:  Malar J       Date:  2009-11-23       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.